Avalo Therapeutics, Inc. (NASDAQ:AVTX) Receives $45.80 Consensus Price Target from Analysts

Shares of Avalo Therapeutics, Inc. (NASDAQ:AVTX) have received a consensus rating of “Moderate Buy” from the fourteen research firms that are presently covering the stock, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation and thirteen have assigned a buy recommendation to the company. The average 12 month price target among brokerages that have covered the stock in the last year is $45.10.

Several research analysts recently commented on AVTX shares. Mizuho raised their price objective on shares of Avalo Therapeutics from $39.00 to $45.00 and gave the stock an “outperform” rating in a report on Thursday, May 14th. Bank of America started coverage on Avalo Therapeutics in a research report on Friday, June 12th. They set a “buy” rating and a $35.00 target price on the stock. BTIG Research reiterated a “buy” rating and issued a $58.00 price target on shares of Avalo Therapeutics in a research report on Tuesday, June 16th. Citizens Jmp decreased their price objective on Avalo Therapeutics from $62.00 to $55.00 and set a “market outperform” rating on the stock in a research note on Thursday, May 14th. Finally, Piper Sandler reissued an “overweight” rating and set a $60.00 price objective (up from $48.00) on shares of Avalo Therapeutics in a report on Monday, May 11th.

Avalo Therapeutics Stock Performance

Shares of AVTX opened at $19.45 on Friday. Avalo Therapeutics has a fifty-two week low of $8.41 and a fifty-two week high of $24.27. The business has a 50-day moving average of $17.69 and a 200 day moving average of $16.41. The firm has a market cap of $1.04 billion, a P/E ratio of -4.45 and a beta of 0.80.

Avalo Therapeutics (NASDAQ:AVTX) last released its quarterly earnings data on Thursday, August 6th. The company reported ($0.83) EPS for the quarter, missing the consensus estimate of ($0.58) by ($0.25). As a group, research analysts predict that Avalo Therapeutics will post -2.59 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, insider Mittie Doyle sold 1,450 shares of the company’s stock in a transaction that occurred on Tuesday, June 23rd. The shares were sold at an average price of $18.00, for a total transaction of $26,100.00. Following the sale, the insider owned 51,776 shares of the company’s stock, valued at approximately $931,968. This represents a 2.72% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 4.46% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the company. Orbimed Advisors LLC raised its position in shares of Avalo Therapeutics by 39.5% in the third quarter. Orbimed Advisors LLC now owns 1,349,300 shares of the company’s stock worth $17,150,000 after buying an additional 382,300 shares in the last quarter. Affinity Asset Advisors LLC grew its position in Avalo Therapeutics by 27.6% during the first quarter. Affinity Asset Advisors LLC now owns 1,340,840 shares of the company’s stock worth $20,019,000 after buying an additional 289,786 shares in the last quarter. Nantahala Capital Management LLC increased its stake in Avalo Therapeutics by 24.1% in the 3rd quarter. Nantahala Capital Management LLC now owns 1,235,000 shares of the company’s stock worth $15,697,000 after acquiring an additional 240,000 shares during the last quarter. Caligan Partners LP increased its stake in Avalo Therapeutics by 5.8% in the 4th quarter. Caligan Partners LP now owns 881,533 shares of the company’s stock worth $16,009,000 after acquiring an additional 48,200 shares during the last quarter. Finally, Balyasny Asset Management L.P. purchased a new stake in shares of Avalo Therapeutics in the 3rd quarter valued at about $10,390,000. 87.06% of the stock is currently owned by hedge funds and other institutional investors.

Avalo Therapeutics Company Profile

Avalo Therapeutics is a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for cardiometabolic, fibrotic and inflammatory diseases. The company’s proprietary drug-design platform enables the creation of long-acting prodrugs with optimized pharmacokinetic profiles, aiming to improve efficacy, safety and patient adherence. By leveraging this technology, Avalo seeks to address key drivers of disease progression that remain underserved by existing treatments.

Its lead programs include AVTX-002, a first-in-class prodrug candidate designed to inhibit angiotensinogen for the treatment of hypertension and related cardiovascular disorders, and AVTX-006, an early-stage candidate targeting pathways implicated in fibrosis and metabolic dysfunction.